Loading
A phase 1/2 trial of onvansertib and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by University of Kansas Medical Center, now recruiting.
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06736717 by University of Kansas Medical Center, with a registry enrolment figure of 21 participants, started 2025-02 and due to reach its primary completion in 2026-07. Interventions recorded: Onvansertib; NALIRIFOX. Conditions listed: Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas". Sites: United States. No results are recorded here; the registry entry is the source.
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.